D. E. Shaw & Co., Inc. Nuvation Bio Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 47,400 shares of NUVB stock, worth $89,586. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,400
Previous 111,227
57.38%
Holding current value
$89,586
Previous $255,000
50.59%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NUVB
# of Institutions
164Shares Held
151MCall Options Held
1.2KPut Options Held
223K-
Decheng Capital LLC Menlo Park, CA26MShares$49.1 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$30.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$29.7 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$24.7 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$17.4 Million5.46% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $411M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...